Cellular Components and Mechanisms of Oral Tolerance Induction
Overview
Authors
Affiliations
Oral tolerance can be defined as an inhibition of specific immune responsiveness to subsequent parenteral injections of proteins to which an individual or animal has been previously exposed via the oral route. Multiple mechanisms of tolerance are induced by oral-fed antigens, but induction of regulatory CD4 T-cells expressing the transcription factor Foxp3 and the membrane-bound TGF-β stands out as the major players in oral tolerance. Oral antigen administration suppresses several animal models of autoimmune disease, including experimental autoimmune encephalomyelitis, uveitis, thyroiditis, myasthenia, arthritis, and diabetes, but also nonautoimmune inflammatory conditions such as asthma, atherosclerosis, graft rejection, allergy, and stroke. However, human trials have produced mixed results, and a great deal remains to be learned about the mechanisms of oral tolerance before it can be successfully applied to people. In this review, we highlight the cellular components involved in oral tolerance induction. A deep knowledge of these intricate cell interactions will pave the way for a successful application of antigen tolerance to treat autoimmune and nonautoimmune inflammatory diseases.
Seefeld M, Templeton E, Lehtinen J, Sinclair N, Yadav D, Hartwell B Front Immunol. 2024; 15:1419527.
PMID: 39286244 PMC: 11403286. DOI: 10.3389/fimmu.2024.1419527.
Systemic effects of oral tolerance in bone healing.
Costa B, Rezende A, Costa L, Neves G, Shimano A, de Oliveira Penoni A Sci Rep. 2023; 13(1):6296.
PMID: 37072616 PMC: 10113372. DOI: 10.1038/s41598-023-33591-4.
Oral tolerance as antigen-specific immunotherapy.
Pinheiro-Rosa N, Torres L, Oliveira M, Andrade-Oliveira M, Guimaraes M, Coelho M Immunother Adv. 2022; 1(1):ltab017.
PMID: 35919733 PMC: 9327124. DOI: 10.1093/immadv/ltab017.
PD-L1 and XCR1 dendritic cells are region-specific regulators of gut homeostasis.
Moreira T, Mangani D, Cox L, Leibowitz J, Lobo E, Oliveira M Nat Commun. 2021; 12(1):4907.
PMID: 34389726 PMC: 8363668. DOI: 10.1038/s41467-021-25115-3.
Preclinical development of plant-based oral immune modulatory therapy for haemophilia B.
Srinivasan A, Herzog R, Khan I, Sherman A, Bertolini T, Wynn T Plant Biotechnol J. 2021; 19(10):1952-1966.
PMID: 33949086 PMC: 8486253. DOI: 10.1111/pbi.13608.